SEC Form 4 · accession 0001610717-26-000382
Neumora Therapeutics, Inc. · NMRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Lee Milligan
Officer — See Remarks
Period of report
Aug 20, 2026
Accepted (ET)
Aug 21, 2026 · 7:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001885522
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.52 | Aug 20, 2026 | A | 175,000 | A | — | Aug 20, 2036 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F125% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Remarks
Title: Chief Financial Officer & Principal Accounting Officer